Skip to main content
    G

    Genmab AS (GMAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.57
    +0.20 (+0.39%)

    Market Cap: $31.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Genmab AS (GMAB) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Genmab AS (GMAB) trades at 35.8x trailing earnings and 19.2x sales. Its P/S of 19.2x is above its 5-year median of 12.3x. Its forward P/E is 22.2x. The median P/E across 5 similar companies is 19.3x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 61.3% higher over the next year. Its free cash flow yield is 1.8%.

    MultipleValue
    P/E (trailing)35.8x
    Forward P/E22.2x
    Price to sales19.2x
    Price to book5.1x
    EV/EBITDA58.3x
    Price to FCF57.0x
    EV/FCF62.6x
    PEG4.6
    FCF yield1.8%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 33.8% below 7.7x.

    MultipleCurrent5-year median10-year median
    P/S19.2x12.3xN/A
    P/B5.1x6.6x7.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 101 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 7.0x in 2024 to 40.3x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$30.8040.3x22.6x
    2024$20.877.0x2.6x
    2023$31.848.8x4.5x
    2022$42.3813.7x7.1x
    2021$39.5619.7x7.7x
    2020$40.6617.2x8.6x
    2019$22.3318.0x7.0x
    2018$16.48N/A8.3x
    2017$16.58N/AN/A
    2016$16.58N/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GMAB

    What is GMAB's forward P/E ratio?

    Genmab AS has a forward P/E ratio of 22.2x.

    Is GMAB stock overvalued?

    GNG's valuation label for GMAB is Overvalued. Its P/E of 35.8x compares with a median of 19.3x across 5 similar companies.

    What is GMAB's price to sales ratio?

    Genmab AS has a price to sales ratio of 19.2x.

    What is GMAB's PEG ratio?

    Genmab AS has a PEG ratio of 4.6.